Figure 5.
Genetic and pharmacological inhibition of PRL2 decrease leukemia burden and extend the survival of mice transplanted with human leukemia cell lines. (A) Western blot analysis for PRL2 in MV-4-11 cells transduced with lentiviruses expressing a shCtrl or PRL2 shRNAs (shPRL2 and shPRL2#2). (B) Knocking down of PRL2 significantly decreased the colony formation of MV-4-11 cells (n = 3). Representative images of the colonies are shown. (C) Kaplan-Meier survival curve of sublethally irradiated NSG mice transplanted with 3 × 106 MV-4-11 cells expressing shCtrl or shPRL2 (n = 7 mice group). (D) Flow cytometry quantification of GFP+ cells in PB, BM, and spleen of NSG mice transplanted with MV-4-11 cells expressing shCtrl or shPRL2 (n = 3 mice per group). (E-F) The size and weight of spleen from NSG mice transplanted with MV-4-11 cells expressing shCtrl or shPRL2 (n = 3 mice per group). (G) PRLi treatment significantly decreased the colony formation ability in MV-4-11 (n = 3). Representative images of the colonies are displayed. (H) 3 × 106 MV-4-11 cells expressing luciferase were injected into sublethally irradiated NSG mice. One week after the transplantation, NSG mice were treated with DMSO or PRLi (25 mg/kg, ip) daily for 3 weeks. The leukemia burdens in NSG mice were monitored by in vivo imaging system once a week for 3 weeks (n = 5 mice per group). (I) Quantitative results from bioimaging (n = 5 mice per group). (J) Kaplan-Meier survival curve of NSG mice treated with DMSO or PRLi (n = 7 mice per group). (K) Flow cytometry analysis of human CD45+ cells in PB, BM, and spleen of NSG mice transplanted with MV-4-11 cells after 3 weeks of DMSO or PRLi treatment (n = 3 mice per group). (L) PRLi treatment reduced splenomegaly seen in NSG mice transplanted with MV-4-11 cells. (M) The spleen weights of NSG mice transplanted with MV-4-11 cells following 3 weeks of DMSO or PRLi treatment (n = 3 mice per group). Mean values (±SEM) are shown (∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001). DMSO, dimethyl sulfoxide; GFP, green fluorescent protein; PRLi, PRL inhibitor; shCtrl, control shRNA, NSG, NOD-scid IL2Rgammanull.

Genetic and pharmacological inhibition of PRL2 decrease leukemia burden and extend the survival of mice transplanted with human leukemia cell lines. (A) Western blot analysis for PRL2 in MV-4-11 cells transduced with lentiviruses expressing a shCtrl or PRL2 shRNAs (shPRL2 and shPRL2#2). (B) Knocking down of PRL2 significantly decreased the colony formation of MV-4-11 cells (n = 3). Representative images of the colonies are shown. (C) Kaplan-Meier survival curve of sublethally irradiated NSG mice transplanted with 3 × 106 MV-4-11 cells expressing shCtrl or shPRL2 (n = 7 mice group). (D) Flow cytometry quantification of GFP+ cells in PB, BM, and spleen of NSG mice transplanted with MV-4-11 cells expressing shCtrl or shPRL2 (n = 3 mice per group). (E-F) The size and weight of spleen from NSG mice transplanted with MV-4-11 cells expressing shCtrl or shPRL2 (n = 3 mice per group). (G) PRLi treatment significantly decreased the colony formation ability in MV-4-11 (n = 3). Representative images of the colonies are displayed. (H) 3 × 106 MV-4-11 cells expressing luciferase were injected into sublethally irradiated NSG mice. One week after the transplantation, NSG mice were treated with DMSO or PRLi (25 mg/kg, ip) daily for 3 weeks. The leukemia burdens in NSG mice were monitored by in vivo imaging system once a week for 3 weeks (n = 5 mice per group). (I) Quantitative results from bioimaging (n = 5 mice per group). (J) Kaplan-Meier survival curve of NSG mice treated with DMSO or PRLi (n = 7 mice per group). (K) Flow cytometry analysis of human CD45+ cells in PB, BM, and spleen of NSG mice transplanted with MV-4-11 cells after 3 weeks of DMSO or PRLi treatment (n = 3 mice per group). (L) PRLi treatment reduced splenomegaly seen in NSG mice transplanted with MV-4-11 cells. (M) The spleen weights of NSG mice transplanted with MV-4-11 cells following 3 weeks of DMSO or PRLi treatment (n = 3 mice per group). Mean values (±SEM) are shown (∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001). DMSO, dimethyl sulfoxide; GFP, green fluorescent protein; PRLi, PRL inhibitor; shCtrl, control shRNA, NSG, NOD-scid IL2Rgammanull.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal